Cannabigerol
The "mother cannabinoid" — biosynthetic precursor to all major cannabinoids
Cannabigerol (CBG) is the biosynthetic precursor from which THC, CBD, and CBC are all derived. Present in low concentrations in most cannabis cultivars, CBG has emerged as one of the most therapeutically promising minor cannabinoids, with strong preclinical evidence for neuroprotection, anti-inflammation, and antibacterial activity.
Primary Receptors & Targets
CBG's pharmacological profile is distinct from both THC and CBD. It acts as a partial agonist at both CB1 and CB2 receptors — unlike CBD, which has minimal direct receptor binding. This partial agonism may explain some of CBG's unique effects, including appetite stimulation without psychoactivity.
CBG's neuroprotective effects are primarily mediated through PPARγ receptor activation, which regulates inflammation, cell survival, and mitochondrial function. PPARγ agonism reduces neuroinflammation and oxidative stress — two key drivers of neurodegenerative disease progression.
CBG also acts as an α2-adrenoceptor agonist, which may contribute to its analgesic and antidepressant effects, and as a TRPV1 antagonist, which modulates pain signaling. Its antibacterial mechanism against MRSA appears to involve disruption of bacterial cell membrane integrity — a mechanism distinct from conventional antibiotics, which is significant given the growing crisis of antibiotic resistance.
Multiple animal model studies show significant neuroprotection; human trials not yet completed.
2013 study in mice showed CBG reduced inflammation and nitric oxide production in colitis model.
2020 ACS Infectious Diseases study: CBG highly effective against MRSA biofilms at topically achievable concentrations.
CBG reduces intraocular pressure in animal models; may act via CB1 receptors in the trabecular meshwork.
CBG most effective of five cannabinoids tested at inhibiting bladder muscle contractions in a 2015 study.
CBG doubled food intake in rats without the anxiety associated with THC-induced appetite stimulation.
Evidence levels reflect the current state of clinical and preclinical research. Preliminary evidence does not constitute medical advice. Consult a healthcare provider before using cannabinoids therapeutically.
Neurochemistry International
CBG reduced neuroinflammation, oxidative stress, and caspase-3 activation in a 3-NP mouse model of Huntington's disease, outperforming CBD on several measures.
ACS Infectious Diseases
CBG demonstrated potent antibacterial activity against MRSA biofilms at concentrations achievable with topical application; identified as a promising lead compound for antibiotic development.
Biochemical Pharmacology
CBG reduced colon weight, inflammation markers, and nitric oxide production in a murine colitis model, suggesting therapeutic potential for IBD.
Psychopharmacology
CBG doubled food intake in satiated rats without producing the anxiety-like behavior associated with THC, suggesting a distinct appetite-stimulating mechanism.
Understanding CBG requires understanding cannabinoid biosynthesis. All cannabinoids begin as CBGA (cannabigerolic acid), synthesized in the cannabis plant from olivetolic acid and geranyl pyrophosphate. Three enzymes then convert CBGA into the three major cannabinoid precursors: THCA synthase produces THCA, CBDA synthase produces CBDA, and CBCA synthase produces CBCA. The relative activity of these enzymes determines the cannabinoid profile of a given cultivar. In high-THC cultivars, most CBGA is converted to THCA; in high-CBD hemp, most becomes CBDA. Selective breeding for reduced synthase activity produces CBG-rich cultivars with elevated residual CBGA/CBG.
CBG is increasingly recognized as an important contributor to the entourage effect in full-spectrum cannabis products. Research comparing full-spectrum extracts to CBD isolate has found that the presence of CBG and other minor cannabinoids significantly modulates CBD's pharmacological activity. CBG's partial CB1/CB2 agonism, PPARγ activation, and α2-adrenoceptor activity add pharmacological dimensions that CBD alone does not provide. Products with standardized, therapeutically meaningful CBG concentrations — not trace amounts — are the ones most likely to deliver the benefits documented in research.